302 related articles for article (PubMed ID: 9241100)
1. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets.
Osamah H; Mira R; Sorina S; Shlomo K; Michael A
Br J Clin Pharmacol; 1997 Jul; 44(1):77-83. PubMed ID: 9241100
[TBL] [Abstract][Full Text] [Related]
2. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
[TBL] [Abstract][Full Text] [Related]
3. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
Hussein O; Schlezinger S; Rosenblat M; Keidar S; Aviram M
Atherosclerosis; 1997 Jan; 128(1):11-8. PubMed ID: 9051193
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.
Haramaki N; Ikeda H; Takenaka K; Katoh A; Sugano R; Yamagishi S; Matsuoka H; Imaizumi T
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1471-7. PubMed ID: 17379842
[TBL] [Abstract][Full Text] [Related]
5. Time-dependent effect of statins on platelet function in hypercholesterolaemia.
Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Angori P; Auteri A; Bruni F
Eur J Clin Invest; 2002 Dec; 32(12):901-8. PubMed ID: 12534449
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
7. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
9. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
[TBL] [Abstract][Full Text] [Related]
14. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.
Gottsäter A; Anwaar I; Lind P; Mattiasson I; Lindgärde F
Blood Coagul Fibrinolysis; 1999 Apr; 10(3):133-40. PubMed ID: 10357007
[TBL] [Abstract][Full Text] [Related]
15. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
[TBL] [Abstract][Full Text] [Related]
16. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia.
Inami S; Okamatsu K; Takano M; Takagi G; Sakai S; Sano J; Mizuno K
Jpn Heart J; 2004 Nov; 45(6):969-75. PubMed ID: 15655272
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
19. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
20. Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost.
Rindone JP; Arriola G
Clin Ther; 1998; 20(2):340-6. PubMed ID: 9589824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
